Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cohort Study of Liver Disorder Risk with Livmarli in Japanese ALGS and PFIC Patients in CIRCLe Registry
jRCT2031250646Recruiting
- Sponsor
- Takeda
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of maralixibat in Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) (2 cohorts), sponsored by Takeda. Primary endpoints: Percentage of ALGS participants with liver disorder (Outcome Definition 1 - side effects), Percentage of PFIC participants with liver disorder (Outcome Definition 1 - side effects) and 2 more. Started Jan 2026; status: recruiting.
02
Drugs
maralixibat
03
Conditions
Alagille syndrome (ALGS)progressive familial intrahepatic cholestasis (PFIC)
Beyond the preview
Go deeper on jRCT2031250646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250646.